January–December 2008 were approved by the American Academy of Pediatrics, the
Advisory Committee on Immunization Practices of the Centers for Disease Control and …

The past century has seen the use of a number of vaccines for prevention and control of
meningococcal disease with varied success. The use of polysaccharide vaccines for the …

Most invasive meningococcal disease in Canada is now caused by serogroup B organisms.
A vaccine directed against this serogroup (4CMenB) is newly licensed in Canada. A …

Background A vaccine against serogroup B Neisseria meningitidis, major cause of bacterial
meningitis in children and adults, has recently been developed. In a context of an increasing …

Summary The United Kingdom is the first country to introduce Bexsero®(GSK Biologicals), a
multicomponent, protein-based vaccine against meningococcal group B (MenB), into the …

Neisseria meningitidis (the meningococcus) is a Gram-negative diplococcus, which causes
meningitis and septicaemia with a high case fatality rate and many survivors suffering from …

A mass vaccination campaign with the 4CMenB vaccine (Bexsero®; Novartis
Pharmaceutical Canada Inc) was launched in a serogroup B endemic area in Quebec. A …

In accordance with its mandate to provide guidance to Member States on healthpolicy
matters, WHO issues a series of regularly updated position papers on vaccines and …

Abstract Objectives Meningococcal C (MenC) vaccination was introduced in the French
vaccination calendar in 2010 to reduce the incidence of invasive meningococcal C disease …

Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine was
recently licensed for use in Europe. There are currently no data on the persistence of …